KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Jazz Pharmaceuticals (JAZZ) Other Non-Current Liabilities (2016 - 2025)

Historic Other Non-Current Liabilities for Jazz Pharmaceuticals (JAZZ) over the last 15 years, with Q3 2025 value amounting to $108.9 million.

  • Jazz Pharmaceuticals' Other Non-Current Liabilities fell 185.54% to $108.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $108.9 million, marking a year-over-year decrease of 185.54%. This contributed to the annual value of $86.6 million for FY2024, which is 1731.44% down from last year.
  • Latest data reveals that Jazz Pharmaceuticals reported Other Non-Current Liabilities of $108.9 million as of Q3 2025, which was down 185.54% from $93.7 million recorded in Q2 2025.
  • Jazz Pharmaceuticals' 5-year Other Non-Current Liabilities high stood at $137.8 million for Q3 2021, and its period low was $86.6 million during Q4 2024.
  • Over the past 5 years, Jazz Pharmaceuticals' median Other Non-Current Liabilities value was $109.2 million (recorded in 2023), while the average stood at $112.3 million.
  • Per our database at Business Quant, Jazz Pharmaceuticals' Other Non-Current Liabilities soared by 1773.53% in 2022 and then crashed by 2152.38% in 2024.
  • Jazz Pharmaceuticals' Other Non-Current Liabilities (Quarter) stood at $117.0 million in 2021, then decreased by 8.71% to $106.8 million in 2022, then fell by 1.93% to $104.8 million in 2023, then fell by 17.31% to $86.6 million in 2024, then grew by 25.74% to $108.9 million in 2025.
  • Its last three reported values are $108.9 million in Q3 2025, $93.7 million for Q2 2025, and $91.1 million during Q1 2025.